Australia Approves Groundbreaking Treatment for Blood Cancer

Australian blood cancer patients who develop complications after life-saving transplants now have access to a groundbreaking new treatment that targets the root causes of their condition.

The Therapeutic Goods Administration has approved NIKTIMVO for chronic graft-versus-host disease, a serious condition affecting 40 to 50 percent of Australians who receive donor stem cell or bone marrow transplants. This makes Australia the first country to approve the therapy since the US authorized it last year.

Chronic graft-versus-host disease occurs when donated stem cells attack healthy tissues in the patient's body, typically appearing four to six months after transplant. The condition can affect multiple organs, causing symptoms ranging from skin rashes and joint stiffness to potentially life-threatening organ failure.

About 600 Australians receive donor stem cell transplants each year to treat blood cancers. For those who develop this complication, almost half will need to try at least three different therapies, highlighting how desperately new options are needed.

Professor Jeff Szer, a clinical haematologist at Peter MacCallum Cancer Centre, explained that the therapy addresses a significant gap in care. "The Australian approval of NIKTIMVO is welcome news and will provide an important new treatment option for patients with chronic GVHD who continue to progress on other therapies," he said.

The treatment works differently from existing options by specifically targeting the inflammation and tissue scarring that drive the disease throughout the body. In clinical trials involving 241 patients across 16 countries, 74 percent of people responded to the therapy, and 60 percent maintained their improvement at 12 months.

Why This Inspires

The story behind this approval makes it especially meaningful for Australia. Scientists at QIMR Berghofer made the world-first discovery back in 2014, identifying both the cellular process causing the disease and the antibody that could block it. That pioneering Australian research laid the foundation for developing this therapy, which is now returning home to help local patients.

The treatment has been fast-tracked through priority review and approved for adults and children six years and older who haven't responded to at least two other therapies. Specialised Therapeutics is currently working to make the therapy available through the Pharmaceutical Benefits Scheme, which would ensure eligible patients can access it affordably.

For patients living with debilitating symptoms that severely impact their quality of life and daily function, this represents genuine hope where options were running out.